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Macrocyclic lactone (ML) drugs inhibit pharyngeal pumping, motility and egg laying in parasitic nema-
todes. Previous work has indicated that in vitro effects on worm feeding occurred at lower ivermectin
concentrations than effects on worm motility, suggesting that the pharynx musculature was a more
important target site for the ML drugs than somatic musculature. We have reassessed this issue of rela-
tive sensitivity by examining the response of drug-susceptible and -resistant adult Haemonchus contortus
worms to abamectin in vitro using both feeding and motility assays. The motility assay involved obser-
vation of changes in the form and degree of movement of individual worms in response to the drug. A
comparison of the data from the two assays indicated that worm motility was affected at drug concen-
trations below those required to inhibit feeding. Analysis of the motility data using different levels of sen-
sitivity (varying in the degree to which they accounted for subtle vs. more profound changes in worm
motility) provided an explanation as to why earlier reports had observed feeding to be the more sensitive
target. Motility IC50 values shifted from being less than feeding IC50s to being greater than the feeding
IC50s as the motility assay analysis method became less sensitive. The present study indicates that when
sensitive worm motility assessment methods are utilised, worm motility is affected at lower abamectin
concentrations than worm feeding, and hence highlights somatic musculature as a more important target
site for this ML drug, and most likely for ML drugs in general.
Crown Copyright  2011 Australian Society for Parasitology Published by Elsevier Ltd.
Open access under CC BY-NC-ND license.1. Introduction
Macrocyclic lactones (MLs) are broad spectrum anthelmintics
used to control nematode parasites of animals and humans. They
increase the permeability of muscle cell membranes to chloride
ions by opening glutamate-gated chloride channels, resulting in
inhibition of pharyngeal pumping, motility and egg laying (Martin,
1997; Köhler, 2001). However, the distribution of ML target sites
within the worm body is unclear. There has been a deal of debate
over the years as to the relative importance of inhibition of pharyn-
geal pumping or motility in the anthelmintic activity of the drugs.
Geary et al. (1993) showed that feeding by Haemonchus contortus
adults in vitro was reduced at concentrations much lower than
those required to inhibit motility, as measured using a motility
metre. The greater sensitivity of pharyngeal pumping to the effects
of the drug suggested that this was the more important site of
action of the drug. Similarly, Richards et al. (1995) reported that
the EC50s for effects of ivermectin on ingestion by Ancylostoma
ceylanicum and Necator americanus adult worms in vitro were
approximately one order of magnitude less than for motility (asty for Parasitology Published by El
).measured by classing worms as either active or inactive) within
each species. These observations on pharyngeal sensitivity to MLs
were subsequently supported by studies which located ivermec-
tin-sensitive glutamate gated chloride ion channels in the pharynx
musculature of various nematode species (Martin, 1996; Laughton
et al., 1997), as well as direct measurements of inhibition of
pharyngeal pumping activity (Brownlee et al., 1997; Sheriff et al.,
2002).
This difference in feeding and motility sensitivity allows
ivermectin to be used as a chemical ligature. Worms remain alive
and show signiﬁcant levels of movement in the presence of iver-
mectin at concentrations that completely inhibited pharyngeal
pumping. A number of studies with H. contortus have used this
ligature approach to study cuticular uptake of various materials
(Sims et al., 1996; Kotze and McClure, 2001; Colgrave et al., 2010).
The suggestion that the pharynx was the most important target
site for MLs was, however, questioned by observations on worm
expulsion kinetics by Gill and Lacey (1998). They noted that
H. contortus and Trichostrongylus colubriformis worms were
expelled from sheep between 8 and 10 h post treatment with iver-
mectin. This rapid expulsion suggested that paralysis of the so-
matic musculature was the most important factor leading to
expulsion, as effects of worm feeding would be expected to take
much longer to deplete energy reserves sufﬁciently to causesevier Ltd. Open access under CC BY-NC-ND license.
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worms were feeding at normal levels within sheep during the per-
iod 4–5 h after the host animal was treated with ivermectin, that is,
just 3 h before expulsion was expected to occur. This further ques-
tioned the role of feeding inhibition in the in vivo action of MLs.
In comparing adult worm in vitro motility data (Geary et al.,
1993) with the in vivo effects of MLs on adult worms within host
animals (Gill and Lacey, 1998), it was apparent that a relationship
between observed reduction in degree of movement in vitro and
the ability of a worm to maintain its position within the host intes-
tinal tract had not been established. That is, it was unclear what
would be the effect on the ability of a worm to maintain its posi-
tion in the gut after exposure to a drug concentration that had been
shown to cause a certain percentage reduction in motility in vitro
as measured by a motility metre, as used by Geary et al. (1993).
Hence, the ability of in vitro motility assays to reﬂect the conse-
quence of drug exposure in vivowas unclear. This raised a question
as to the sensitivity of in vitromotility measurements, and whether
assumptions of relative in vivo effects based on relative sensitivi-
ties in in vitro motility and feeding assays were valid. While com-
plete, or almost complete, paralysis was easily observable in vitro,
and would be expected to be associated with worm expulsion
in vivo, more subtle effects on worm motility which may have sig-
niﬁcant consequences in vivo may not be detectable by standard
in vitro motility assays.
The present study therefore aimed to observe the effects of the
ML abamectin on movement of individual worms in vitro by careful
observation of subtle changes in both the degree of movement and
its distribution along the body of the worm in response to the drug.
Such observations were then compared to the effect of the drug on
worm feeding levels. In order to compare our motility assessment
method to the outputs of previous motility studies, we examined
the effects of changing the sensitivity of the motility assay data
analysis on motility/feeding comparisons.Table 1
Motility scoring system.
Motility
score
Description
4 Rapid sinusoidal movement in whole body or in >90% of body
Worm able to rise up from the base of the dish
3 Signiﬁcant movement:
movement spread over >75% of the body; worm on base of dish
no tight coiling (tight coil 6 2 mm diameter)
2 Limited movement:
<75% of body moving;
movement limited to one or both ends of body, central area of
body immotile;
or, coiled:
tight coils observed, regardless of overall degree of body
movement;
constant coiling or transient formation of at least one tight coil
during observation period
1 Minimal movement:
minor movement at either end of body only,
<10% of body moving (most commonly seen as minimal
movement at anterior end only)
0 No movement2. Materials and methods
2.1. Recovery of adult H. contortus worms
The use of sheep to provide adult worms for in vitro assays was
approved by the DEEDI animal ethics committee, Queensland Gov-
ernment (approval number SA 2010/07/321). Sheep were infected
with 5,000 infective stage larvae of either the drug-susceptible Kir-
by isolate of H. contortus (Albers and Burgess, 1988) or the multi-
drug-resistant Wallangra 2003 isolate (Love et al., 2003). This iso-
late has been selected further using a full dose of moxidectin over
at least ﬁve generations since it was originally isolated from the
ﬁeld. The sheep were euthanized 5–7 weeks after infection and
the adult worms were gently scraped from the lining of the aboma-
sum into 0.1% (w/v) agar in PBS, containing 20 U/ml penicillin so-
dium, 20 lg/ml streptomycin sulphate, and 0.1% (w/v) glucose,
on a warming tray set at 42 C. The worms were picked individu-
ally into another dish, and then into a further dish in order to sep-
arate them from any digesta material. They were ﬁnally transferred
to an RPMI-based medium (modiﬁed from Kotze and McClure,
2001) and held in this solution for at least 2 h at 37 C. The medium
consisted of: RPMI-1640 (with L-glutamine) 10.4 g/L, 10 mM
HEPES, 10 mM NaHCO3, 0.8% (w/v) glucose, 200 U/ml penicillin so-
dium, 200 lg/ml streptomycin sulphate, 2.5 lg/ml amphotericin B,
8 lg/ml tylosin, at pH 7.0.
Worms were then placed into a dish containing fresh medium
on a warming tray. Individual worms moving in a smooth sinusoi-
dal fashion were transferred to 6-well plates containing 2.88 ml of
culture medium per well (=the medium described above plus 20%
(v/v) foetal bovine serum, Gibco). The numbers of worms added toeach well was either 5, 10 or 15, depending on the numbers avail-
able on each experimental day. The wells then received either 6 ll
DMSO (no-drug control wells) or 6 ll of various serially-diluted
abamectin solutions in DMSO (ﬁnal DMSO concentration 0.2%).
The ﬁnal abamectin assay concentrations consisted of 8-fold dilu-
tions over the range: 0.0055–11,500 nM. Plates were placed into
a modular incubator (volume 10 L), and a gas mixture (5% O2,
20% CO2, in nitrogen) was passed through for 3 min. The incubators
were sealed and placed at 37 C for 24 h. In order to quantify worm
feeding levels over the 24–48 h incubation interval, the assay
plates were removed from the incubator at the 24 h time point,
and a feeding substrate was added to each well. A solution of ﬂuo-
rescein isothiocyanate (FITC)-dextran (average molecular weight
40,000 Da) (Sigma) was prepared at 25 mg/ml in culture medium,
and 120 ul was added to each assay well, except for a small num-
ber of ﬂuorescence-control (no dextran) wells. The plates were re-
gassed and returned to the incubator for a further 24 h.
A number of separate experiments were performed as follows:
the effects of abamectin on feeding levels were assessed in four or
three separate experiments for the Kirby and Wallangra isolates,
respectively; effects of abamectin on motility were assessed in
two of these experiments for both the Kirby and Wallangra iso-
lates. That is, two separate motility experiments were performed
with fresh batches of worms for both the Kirby and Wallangra iso-
lates. Each experiment consisted of 2–3 assay wells at each drug
concentration, alongside 4–6 control wells for feeding, or 6–12
control wells for motility.2.2. Worm motility assay
After a total incubation period of 48 h, worms were picked from
each assay well and placed into a dish held on the warming tray
containing medium without serum, and viewed under a 12 cm
diameter illuminated magnifying lens. Any clumped worms were
gently teased apart using two sharpened probes. The operator then
scored the motility of each individual worm using the system de-
scribed in Table 1. Firstly, the worms moving freely in a sinusoidal
fashion, and rising up from the bottom of the dish (score 4) were
counted and removed to a rinsing dish containing mediumwithout
serum. The remaining worms were moved into the four quadrants
of the dish corresponding to those moving with scores of 3, 2, 1 or 0
as described in Table 1. Those showing signiﬁcant movement at a
score 3 level were transferred to the rinse dish, allowing further
Fig. 1. Effects of abamectin on uptake of FITC-dextran by Kirby andWallangra adult
H. contortus in vitro. Each data point represents mean ± SE, n = 4 or 3 separate
experiments for Kirby and Wallangra, respectively, each with 2–3 assay wells at
each drug concentration, and 4–6 control (no drug) wells. Where SEs are not visible,
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were then observed for a further 30–40 s, and their placement into
the 2, 1, and 0 score categories was conﬁrmed. Finally, all the
worms were picked into the rinse dish. The worms were then
rinsed in two more dishes of medium, and ﬁnally in PBS, before
being transferred to a 2 ml screw-top plastic tube containing
approximately 0.3 g of 1 mm diameter zirconia beads (BioSpec
Products) to be further processed for feeding level measurements
(described below). All worms used in this study were scored for
motility by the same operator. This operator scored the assays in
a blinded fashion, with assay wells labelled only with sequential
numbers, not treatment descriptions.
2.3. Worm feeding levels
Feeding levels in worms during the 24–48 h interval were quan-
tiﬁed by measuring the amount of FITC-dextran taken up by the
worms during this time period of the assay. The processing of
worms for feeding measurements was undertaken after they had
been scored for motility. Borate buffer (0.5 ml of 10 mM Na2-
B4O710H2O, pH 9.0) was added to each screw top vial, and the
worms were homogenised by shaking the vials in a FastPep-24
sample preparation system (MP Biomedicals) for 40 s at full speed.
The vials were then spun at 10,000g for 10 min, and 0.3 ml of
supernatant was transferred to the wells of a 96-well black-sided
ﬂuorescence microplate (Greiner Bio-One). Fluorescence was mea-
sured at excitation and emission wavelengths of 485 and 535 nm,
respectively, using a Tecan Spectraﬂuor Plus.
2.4. Data analysis
The number of worms at each motility score in drug-treated or
control wells was expressed as a percentage of the total number of
worms in the well. These % values were then averaged across the
two replicate experiments (separately for each isolate). The mean
worm %s at each motility score where then compared in control
and drug-treated assays using two way ANOVA (GraphPad Prism
5, P = 0.05), with motility score and abamectin concentration as
factors, in order to determine if abamectin exposure altered the
% of worms within each motility score compared to controls.
In order to deﬁne motility dose responses, and hence be able to
compare feeding and motility dose responses, we expressed the
number of worms showing certain degrees of movement (motility
scores) in drug-treated assays as a % of the number of worms
showing the same degree of movement in control assays. In aiming
not only to compare feeding and motility responses, but also to
examine the relationship between the sensitivity of our motility
assay and the motility/feeding comparisons, we examined the
motility scores in three ways:
 Most sensitive: only the number of score 4 worms in each assay
well was considered in comparing drug-treated assays to con-
trols. In this way we examined the ability of abamectin to
reduce the motility of worms from a level 4 score to any of
the lower scores compared to control assays. This represented
abamectin concentrations having effects ranging from extreme
inhibition of motility (an increase in the frequency of scores 2,
1, 0 in drug treated assays compared to controls), as well as
mild inhibition of motility (any transition of worms from score
4 to 3 in response to drug treatment).
 Intermediate sensitivity: the numbers of worms showing scores
4 and 3 were combined, and then compared between control
and drug-treated wells. Hence, this analysis examined just the
ability of abamectin to reduce worms to a level of limited, min-
imal or zero movement (scores 2, 1, 0) compared to the num-bers of worms showing score 4 and 3 levels of motility in
drug-treated and control assays, and did not detect the score
4 to 3 transition.
 Least sensitive: worm numbers for scores 4, 3 and 2 in each
assay well were combined, and then compared in control and
drug-treated wells. Hence, this analysis measured the ability
of abamectin to reduce worms to a level of minimal movement
(score 1) or no movement (0) compared to the numbers of
worms showing score 4, 3 and 2 levels of motility in drug-trea-
ted and control assays. This type of assessment did not take into
account the subtle changes in movement which would have
otherwise been highlighted by considering scores 4 and 3
separately.
For quantiﬁcation of feeding levels, the ﬂuorescence present in
drug-treated worms at each drug concentration (after correction
for auto-ﬂuorescence in no-dextran controls) was expressed as a
% of the ﬂuorescence measured in control worms (also after correc-
tion using no-dextran controls). Feeding and motility dose re-
sponse data were analysed using non-linear regression to
generate IC50 values with 95% conﬁdence intervals (CIs) (GraphPad
Prism 5). Differences between IC50 values were evaluated using
non-overlap of 95% CIs as the criterion.
3. Results
Dose responses describing the effects of abamectin on worm
feeding levels are shown in Fig. 1. There was a clear separation be-
tween the drug-susceptible Kirby and -resistant Wallangra iso-
lates, with a resistance ratio at the IC50 of 559-fold (Table 2).
The distribution patterns for motility scores in control assays
for the Kirby and Wallangra isolates are shown in Fig. 2. Both iso-
lates showed the presence of approximately equal numbers of
worms with motility scores of 4, 3, 2 or 0. There were lower num-
bers of worms with scores of 1. Within each isolate, there were no
signiﬁcant differences between numbers of worms showing each
motility score (P > 0.05).
Fig. 3 shows the effect of increasing concentrations of abamec-
tin on the numbers of worms showing each motility score, com-
pared to the numbers of worms in control wells showing an
equivalent motility score. The effect of increasing drug concentra-
tion is indicated by moving from left (control) to right (increasingthey are smaller than the data point symbols.
Table 2
Dose response data describing the effects of abamectin on feeding and motility
(analysed using three different levels of sensitivity) of Kirby and Wallangra adult H.
contortus in vitro.
Assay/assessment
method
Kirby Wallangra RRa
IC50
nM
95% CI IC50
nM
95% CI
Feeding 0.16 0.13–0.21 89.4 81.9–
97.6
559
Motility/most sensitive 0.015 0.0088–
0.0257
19.9 ndb 1,327
Motility/intermediate
sensitivity
0.010 0.0047–
0.0222
28.5 9.3–
86.8
2,850
Motility/least sensitive 0.40 0.10–1.58 >11,500 ndc >29,000
a RR = resistance ratio = IC50 Wallangra isolate/IC50 Kirby isolate.
b Not determined; no CI calculated by GraphPad Prism software due to lack of
data points on regression line (see Fig. 4).
c Not determined; no IC50 CI calculated as % motility remained above 80% (see
Fig. 4).
Fig. 2. Frequency distributions of motility scores for Kirby and Wallangra adult H.
contortus in control (no drug) assays. Each column represents mean ± SE, n = 2
separate experiments for each isolate, each with 6–12 replicate control wells (parts
A and D) or 2–3 replicate drug-treated wells (parts B, C, E and F).
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shown here were chosen after consideration of the feeding data
from Fig. 1. The three abamectin concentrations examined in
Fig. 3 for each isolate represented: ﬁrstly, a level at which feeding
was not impacted in Kirby (0.0055 nM, lowest point in Fig. 1), fol-
lowed by the concentration giving an approximately 10% inhibition
of feeding (IC10) (0.044 nM, from Fig. 1), followed by the approxi-
mate feeding IC75 concentration (0.35 nM, from Fig. 1). The rela-
tionship was similar for Wallangra, although at higher abamectin
concentrations: ﬁrstly, a level below the approximate IC10
(2.9 nM, 8-fold lower than the lowest concentration tested in
Fig. 1), the approximate IC10 point (22 nM, from Fig. 1), and the
approximate IC75 point (180 nM). Hence, the concentrations exam-
ined in Fig. 3 represented a range from no effect on feeding, up to a
feeding inhibition of approximately 75%. As the abamectin concen-
tration increased, the numbers of Kirby worms showing motility 4
and 3 scores decreased, alongside an increase in score 1 worms.
The mean % of total worms showing a motility score of four de-
creased 7-fold (24.5% down to 3.5%) relative to controls as the aba-
mectin concentration reached the feeding IC75, while the % of
worms showing a motility score of three decreased from 27% to
zero. Similarly, the numbers of score 4 Wallangra worms de-
creased, while score 2 worms increased, as the abamectin concen-
tration increased. The highest abamectin concentration resulted in
a complete absence of Wallangra worms showing score 4 motility
compared to a 30% presence in control wells. These trends were in
many cases not statistically signiﬁcant, most likely associated with
the large standard errors, particularly at the lower motility scores,
and an n value of only two (duplicate experiments for each isolate).
Despite this, a shift towards lower motility scores as abamectin
concentration increased was apparent. Thus, Fig. 3 indicates that
abamectin concentrations that inhibited feeding by up to 75%
had marked inhibitory effects on the degree and form of movement
shown by the worms in both isolates.
In order to examine the relationship between the sensitivity of
our motility assay scoring system and the feeding assay, we exam-
ined the motility scores by pooling data from the different scoring
levels (representing different assay sensitivity levels). Fig. 4 shows
motility dose responses derived from analysis of the motility data
using the different levels of sensitivity. The feeding assay data from
Fig. 1 is also shown here for comparison. Table 2 shows the IC50
(and 95% CIs) values for the motility data at each of the three sen-
sitivity levels. For both Kirby and Wallangra, the dose response for
the most sensitive and intermediate sensitivity motility analyses
lay to the left of the feeding response (Fig. 4, parts A, B, D and E).
As the motility scoring system became less sensitive (through con-sideration of only more pronounced effects on motility) the motil-
ity dose responses shifted to the right of the feeding responses for
both isolates (parts C and F). This was particularly marked for Wal-
langra which showed very little change in motility over a wide
range of abamectin concentrations using the least sensitive motil-
ity assessment method (part F). Motility IC50 values derived from
the intermediate and most sensitive motility analysis methods
were 16- and 11-fold lower than the feeding IC50 for the Kirby iso-
late (Table 2). These IC50 values were signiﬁcantly less than the
feeding IC50 for the Kirby isolate (as judged by non-overlap of
95% CIs). The equivalent comparisons for Wallangra showed 3-
and 4.5-fold lower motility values compared to feeding, however
these values were not signiﬁcantly different between the two assay
types (CIs could not be calculated for the most sensitive motility
assessment). Both assays produced high resistance ratios in com-
paring Kirby and Wallangra responses, with the ratios determined
by each of the motility scoring systems being greater than that
generated from the feeding assay.
4. Discussion
This study indicates that previous suggestions of greater sensi-
tivity of worm feeding to the effects of MLs in vitro compared to
motility may be incorrect. Firstly, we have shown that wormmotil-
ity is reduced by abamectin concentrations below those required
to inhibit feeding. Secondly, by examining the effect of imposing
Fig. 3. Effects of abamectin on motility of Kirby and Wallangra adult H. contortus
in vitro. Each column represents mean ± SE, n = 2 separate experiments for each
isolate, each with 6–12 replicate control wells, and 2–3 replicate drug-treated wells.
Within an isolate, and within a motility score, columns labelled with ⁄ are
signiﬁcantly different from the corresponding control assay (P < 0.05).
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data we have demonstrated why previous studies comparing rela-
tive sensitivities of feeding and motility may have found the for-
mer to be affected at lower drug concentrations than the latter.
This may be explained by a lack of sensitivity to detect subtle ef-
fects of drug on worm motility using techniques such as motility
metres (Geary et al., 1993) or observation of general levels of
movement by groups of worms conﬁned in bioassay vials (O’Grady
and Kotze, 2004), compared to our observations on the form and
degree of movement in individual worms. The habit of adult H.
contortus to clump in vitro may partly explain the differences in
sensitivity between our assessment methods and the use of a
motility metre or visual observation of groups of worms in vials.
The total amount of movement detectable in worms showing any
signs of clumping may be less than if the worms are teased apart
and hence are completely free to move (as in the present study).
Geary et al. (1993) noted that paralysis by ivermectin was re-
stricted to the mid-body region, while the head and tail showed
apparently normal motility. This is also reﬂected in our scoring sys-tem from Table 1. Similarly, clumped worms tend to thrash the
ends of their body around while the central part remains less mo-
tile as part of the clump. Hence, if the worms are clumped to some
degree, the effects of MLs on the mid body region will be masked,
alongside continued uninhibited movement of the body head and
tail regions. Thus, movement in control vials showing some clump-
ing would not be as distinguishable as it should be from ML-trea-
ted worms. Movement in both cases would be restricted in the mid
body region, by clumping in the former, and drug action alongside
clumping in the latter.
It is clear that while motility is affected at drug concentrations
lower than those required to inhibit feeding, worms are able to sur-
vive and continue to show some movement at drug concentrations
that cause a complete cessation of feeding during the 24–48 h time
period used in the present study (from Fig. 4, using the least sensi-
tive motility analysis method). Thus the use of MLs as in vitro
chemical ligatures, as ﬁrst suggested by Geary et al. (1993), re-
mains unchallenged by the present study as long as some subtle
reductions in motility, particularly in the mid-body region, are
understood to be a consequence of the ligation.
We used abamectin in this study, in contrast to most studies on
the action of ML drugs against parasitic nematodes in vitro which
have used ivermectin, including Geary et al. (1993). Hence our
study speciﬁcally indicates the relative sensitivity of feeding and
body musculature to inhibition by abamectin alone. While aver-
mectins as well as milbemycins are thought to act on the same tar-
get, namely, glutamate gated chlorine ion channels (Martin, 1996,
1997), there are some differences in the relative sensitivities of
worms to the different analogues, suggesting that different recep-
tor subsets may interact with the different analogues. Gill et al.
(1995) found that abamectin was more active (slightly lower IC50
values) than ivermectin in in vitro larval development assays with
drug-susceptible isolates of H. contortus. Resistance patterns to the
two drugs can also vary; for example, Gill et al. (1991) showed that
resistance ratios (at the IC50) towards abamectin in in vitro larval
motility assays with different isolates of H. contortus were in some
cases considerably higher than shown towards ivermectin. Aba-
mectin is generally more effective than ivermectin against ML-
resistant worms in vivo at the equivalent dose rate (0.2 mg/kg)
(for example, Love et al., 2003, H. contortus on Farm N; Little
et al., 2010, Teladorsagia sp. in Trial 9). Hence, while the present
study speciﬁcally demonstrates the relative effects of abamectin
on feeding and motility in adult H. contortus, and therefore most
likely represents a phenomenon generally applicable to ML drugs
given their common mode of action, this remains to be tested
experimentally using a variety of ML analogues as it remains pos-
sible that the observed relative feeding/motility effects may vary
between drugs due to interactions with different receptor subsets.
Very high resistance ratios were obtained for the Wallangra iso-
late compared to Kirby in both the feeding and motility assays. The
relationships between these in vitro resistance levels and in vivo
changes in drug efﬁcacy are unclear, however, the study by Ranjan
et al. (2002) provides a means to compare the Wallangra/Kirby
in vitro and in vivo resistance levels to some extent. This report de-
scribed data from in vivo dose titrations with ivermectin and moxi-
dectin against a susceptible isolate of H. contortus as well as two
isolates which had been pressured separately with one of the drugs
over 22 generations. At the end of this process the ivermectin-se-
lected resistant isolate showed some resistance to ivermectin (efﬁ-
cacy 71%) although no resistance to moxidectin (100% efﬁcacy at a
half dose). The in vivo ivermectin IC50 was increased 61-fold in the
ivermectin-selected isolate compared to the parent susceptible iso-
late. That is, a reduced ivermectin efﬁcacy of 71%, alongside com-
plete susceptibility to moxidectin, was associated with a 61-fold
shift in in vivo IC50. At the time of its isolation from the ﬁeld, the
Wallangra isolate was not affected by a full dose of ivermectin
Fig. 4. Effects of abamectin on motility of Kirby and Wallangra adult H. contortus in vitro, alongside feeding assay dose response data (from Fig. 1). Worm motility data was
analysed at different levels of sensitivity (see text for details): most sensitive (A, D), intermediate sensitivity (B, E), or least sensitive (C, F). Each data point represents
mean ± SE, n = 2 separate experiments for each isolate, each with 6–12 replicate control wells, and 2–3 replicate drug-treated wells. Where SEs are not visible, they are
smaller than the data point symbols.
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tin efﬁcacies of 67% and 84% were reported for two trials (Love
et al., 2003). Since that time, the isolate has been selected at least
ﬁve times using a full dose of moxidectin. It is now largely unaf-
fected by moxidectin treatment as judged through its ability to
establish infections at equivalent levels to the susceptible Kirby
isolate in sheep of similar age and weight despite receiving a full
dose of moxidectin 14 days after the worm dose (Kotze unpub-
lished, animal-house egg count data). Hence, the Wallangra isolate
used in the present study showsmuch higher levels of resistance to
MLs than the ivermectin-pressured isolate of Ranjan et al. (2002)
(zero vs. 71% ivermectin efﬁcacy, very low vs. 100% moxidectin
efﬁcacy). Therefore it may not be unrealistic to consider that the
61-fold shift in in vivo IC50 described by Ranjan et al. (2002) couldbe extended by another order of magnitude for the highly resistant
Wallangra isolate. This would bring it to a level approximating the
in vitro resistance ratios from the present study (559 for feeding,
and 1,327–2,850 for motility). On the other hand, the >29,000
resistance ratio for the least sensitive motility assay assessment
method in the present can be discounted from this in vitro/
in vivo comparison as it most likely represents a level of assay sen-
sitivity removed from that which is relevant to worm expulsion
in vivo. The unrealistic nature of this resistance ratio further sug-
gests that the more subtle motility scoring methods applied in
the present study represent a more accurate appraisal of motility
effects that may be signiﬁcant in vivo.
An important point in regard to the high resistance ratios
shown in Table 2 is that very high resistance ratios do not
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would be required to impact on the worm population in vivo.
Ranjan et al. (2002) showed that the full dose of ivermectin
(0.2 mg/kg) was 111-fold higher than the IC50 for their drug sus-
ceptible isolate, indicating that signiﬁcant shifts in in vivo IC50
can occur before there is any impact on the ability of the standard
drug dose to remove the infection
The in vitro IC50 values shown in Table 2 can be compared to
some extent with the expected concentrations of abamectin in
sheep following in vivo drug treatment. Cerkvenik-Flajs et al.
(2007) reported a maximal abamectin plasma concentration (Cmax)
of 35 nM at a tmax of 1.7 days in ewes following subcutaneous
administration. This plasma concentration is at least 88-fold higher
than the in vitro feeding and motility IC50 values (from Table 2) for
the Kirby isolate which would be expected to be removed from
sheep by drug treatment in vivo. On the other hand, the maximum
plasma concentration is comparable to, or less than, the in vitro
feeding and motility IC50 values for the Wallangra isolate (not
including the least sensitive motility assessment method), as
may be expected given the inability of a standard dose of the drug
to remove a worm population from sheep (abamectin efﬁcacy 19%,
Love et al., 2003).
While we analysed the motility data in the present study using
different levels of sensitivity, and found this to profoundly affect
the assay output, we did not examine changes in the sensitivity
of our feeding assay through, for example, using feeding substrates
differing signiﬁcantly in molecular size. However, it is likely that
there is little difference in feeding assay sensitivity using different
feeding substrates as long as the dimensions of the feed material
do not become prohibitive for uptake through the worm’s mouth
and pharynx. The relative feeding/motility relationship described
for ivermectin by Geary et al. (1993) was apparent usingEscherichia
coli, blue dextran and inulin as feeding substrates alongside the
single motility assessment method (motility metre). This repre-
sented feeding substrate molecular radii ranging from uM
(E. coli) to nm (inulin). The dimensions of the FITC-dextran used
for the present study (radius 4.5 nm) lies at the lower end of this
range.
Two observations on the assays used in this study are worthy of
noting. Firstly, the motility assay described here should be viewed
as being useful only for the study of subtle drug effects rather than
having any general application in drug studies. It is far too labori-
ous and time-consuming to have any application in general drug
discovery studies. It represents a step away from recent efforts to
develop high throughput drug screening methods for drug discov-
ery (for example, Buckingham and Sattelle, 2009; Smout et al.,
2010). However, in challenging the previous motility/feeding bal-
ance of ML action, the present study has illustrated the difference
in drug action assay outputs between an observation-based assay
and a higher throughput motility metre-based assay. Secondly,
the feeding assay described here should be viewed as being of gen-
eral use for examining worm ‘well being’ in response to any drug,
as distinct from its use here as a direct measure of ML action in
inhibiting glutamate-gated chloride ion channels in the pharynx
musculature. A signiﬁcant difference between the assays is illus-
trated by the much larger SEs present on the motility data com-
pared to the feeding assay data (comparison of Figs. 1 and 4).
The subjective and time consuming nature of the motility assay
contrasts clearly with the ability of the feeding assay to readily
quantify anthelmintic effects.
It remains unclear whether the subtle effects on worm motility
that the present study indicates will occur at relatively low ML
drug concentrations are sufﬁcient to cause worm expulsion
in vivo, or whether higher drug concentrations causing feedinginhibition and more severe motility defects are required. However,
it may be expected that inability to move in a normal sinusoidal
fashion, and even mild paralysis in the body mid-section, as seen
in the score 4 to 3, and 3 to 2 transitions in the present study, could
affect the ability of a worm to maintain its position in the host gut.
Despite this uncertainty as to the extent of paralysis (body or pha-
ryngeal musculature) required for worm expulsion, the present
study suggest that motility will most likely be affected before feed-
ing as ML drug concentrations increase in the worm’s environment
following treatment of host animals.
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